Form 8-K - Current report:
SEC Accession No. 0001193125-22-091747
Filing Date
2022-03-31
Accepted
2022-03-31 16:06:28
Documents
14
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d332054d8k.htm   iXBRL 8-K 24747
2 EX-99.1 d332054dex991.htm EX-99.1 59894
6 GRAPHIC g332054sp0001.jpg GRAPHIC 7386
  Complete submission text file 0001193125-22-091747.txt   230427

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sbtx-20220331.xsd EX-101.SCH 2861
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbtx-20220331_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbtx-20220331_pre.xml EX-101.PRE 11711
8 EXTRACTED XBRL INSTANCE DOCUMENT d332054d8k_htm.xml XML 3474
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Filer) CIK: 0001671858 (see all company filings)

IRS No.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 22792446
SIC: 2834 Pharmaceutical Preparations